No Data
Hualan Vaccine (301207.SZ) has repurchased a total of 5.6008 million shares, costing 99.1311 million yuan.
Huaren Vaccine (301207.SZ) announcement, as of August 31, 2024, the company traded through centralized bidding...
Hualan Vaccine: 2024 Semi-Annual Report
Hualan Vaccine: 2024 Semi-Annual Report Summary
Hualan Vaccine (301207.SZ): The net income in the first half of the year was 25.2744 million yuan, a year-on-year decrease of 76.65%.
On August 29th, Gelonhui announced its semi-annual report for 2024, with reported revenue of 35.529 million yuan, a year-on-year decrease of 76.25%; net income attributable to shareholders of listed companies was 25.2744 million yuan, a year-on-year decrease of 76.65%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -21.3215 million yuan; basic earnings per share was 0.0421 yuan.
Huawei Health Vaccine (301207.SZ) released its semi-annual performance, with a net income of 25.2744 million yuan, a year-on-year decrease of 76.65%.
Hualan Vaccine (301207.SZ) released its semi-annual report for 2024, during which the company achieved revenue of 3...
Many Still Looking Away From Hualan Biological Vaccine Inc. (SZSE:301207)
No Data
